Bionano Genomics stockholders elect Luderer and Vuori as directors; pay vote and auditor ratified

Bionano Genomics, Inc.

Elected Albert Luderer (847,601 for) and Kristiina Vuori (867,474 for) as Class II directors for three-year terms.
Advisory vote on named executive officer compensation passed with 697,999 for, 216,553 against, 76,839 abstentions.
Ratification of BDO USA as independent auditor for fiscal 2026 passed with 3,770,715 votes for, 206,541 against.
Quorum was 38.1% of 11,091,615 shares outstanding (4,225,995 shares present).
Broker non-votes totaled 3,234,604 on director elections and compensation proposals.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bionano Genomics, Inc. shareholders approved Election of Directors at the 2026-05-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 1. Election of Directors. The Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Albert Luderer, Ph.D. 847,601 143,790 3,234,604 Kristiina Vuori, M.D., Ph.D. 867,474 123,917 3,234,604

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bionano Genomics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,770,715 206,541 248,739 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bionano Genomics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-05-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 697,999 216,553 76,839 3,234,604

View on SEC.gov

162 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-26-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.